232 related articles for article (PubMed ID: 30216109)
1. Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle.
Petrosino JM; Leask A; Accornero F
FASEB J; 2019 Feb; 33(2):2047-2057. PubMed ID: 30216109
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).
Morales MG; Cabrera D; Céspedes C; Vio CP; Vazquez Y; Brandan E; Cabello-Verrugio C
Cell Tissue Res; 2013 Jul; 353(1):173-87. PubMed ID: 23673415
[TBL] [Abstract][Full Text] [Related]
3. Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β.
Rebolledo DL; González D; Faundez-Contreras J; Contreras O; Vio CP; Murphy-Ullrich JE; Lipson KE; Brandan E
Matrix Biol; 2019 Sep; 82():20-37. PubMed ID: 30716392
[TBL] [Abstract][Full Text] [Related]
4. CCN2 participates in overload-induced skeletal muscle hypertrophy.
Petrosino JM; Longenecker JZ; Angell CD; Hinger SA; Martens CR; Accornero F
Matrix Biol; 2022 Feb; 106():1-11. PubMed ID: 35045313
[TBL] [Abstract][Full Text] [Related]
5. Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis.
Riquelme-Guzmán C; Contreras O; Brandan E
Am J Physiol Cell Physiol; 2018 Apr; 314(4):C415-C427. PubMed ID: 29351412
[TBL] [Abstract][Full Text] [Related]
6. CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy.
Morales MG; Cabello-Verrugio C; Santander C; Cabrera D; Goldschmeding R; Brandan E
J Pathol; 2011 Dec; 225(4):490-501. PubMed ID: 21826667
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.
Cabello-Verrugio C; Morales MG; Cabrera D; Vio CP; Brandan E
J Cell Mol Med; 2012 Apr; 16(4):752-64. PubMed ID: 21645240
[TBL] [Abstract][Full Text] [Related]
8. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
[TBL] [Abstract][Full Text] [Related]
9. Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF).
Rebolledo DL; Lipson KE; Brandan E
Matrix Biol Plus; 2021 Aug; 11():100059. PubMed ID: 34435178
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Pathological Activities of CCN2/CTGF in Muscle Dystrophy.
Acuña MJ; Brandan E
Methods Mol Biol; 2017; 1489():513-521. PubMed ID: 27734402
[TBL] [Abstract][Full Text] [Related]
11. CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases.
Gonzalez D; Brandan E
Mol Neurobiol; 2019 Aug; 56(8):5911-5916. PubMed ID: 30689195
[TBL] [Abstract][Full Text] [Related]
12. Myofiber-specific inhibition of TGFβ signaling protects skeletal muscle from injury and dystrophic disease in mice.
Accornero F; Kanisicak O; Tjondrokoesoemo A; Attia AC; McNally EM; Molkentin JD
Hum Mol Genet; 2014 Dec; 23(25):6903-15. PubMed ID: 25106553
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.
Gibertini S; Zanotti S; Savadori P; Curcio M; Saredi S; Salerno F; Andreetta F; Bernasconi P; Mantegazza R; Mora M
Cell Tissue Res; 2014 May; 356(2):427-43. PubMed ID: 24723230
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model.
Gonzalez D; Rebolledo DL; Correa LM; Court FA; Cerpa W; Lipson KE; van Zundert B; Brandan E
Hum Mol Genet; 2018 Aug; 27(16):2913-2926. PubMed ID: 29860398
[TBL] [Abstract][Full Text] [Related]
15. Pathological analysis of muscle hypertrophy and degeneration in muscular dystrophy in gamma-sarcoglycan-deficient mice.
Sasaoka T; Imamura M; Araishi K; Noguchi S; Mizuno Y; Takagoshi N; Hama H; Wakabayashi-Takai E; Yoshimoto-Matsuda Y; Nonaka I; Kaneko K; Yoshida M; Ozawa E
Neuromuscul Disord; 2003 Mar; 13(3):193-206. PubMed ID: 12609501
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation.
Vial C; Zúñiga LM; Cabello-Verrugio C; Cañón P; Fadic R; Brandan E
J Cell Physiol; 2008 May; 215(2):410-21. PubMed ID: 18064627
[TBL] [Abstract][Full Text] [Related]
17. Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway.
Lorts A; Schwanekamp JA; Baudino TA; McNally EM; Molkentin JD
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10978-83. PubMed ID: 22711826
[TBL] [Abstract][Full Text] [Related]
18. The pro-fibrotic connective tissue growth factor (CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle.
Morales MG; Acuña MJ; Cabrera D; Goldschmeding R; Brandan E
J Cell Commun Signal; 2018 Mar; 12(1):413-421. PubMed ID: 28887614
[TBL] [Abstract][Full Text] [Related]
19. CTGF/CCN2 is an autocrine regulator of cardiac fibrosis.
Dorn LE; Petrosino JM; Wright P; Accornero F
J Mol Cell Cardiol; 2018 Aug; 121():205-211. PubMed ID: 30040954
[TBL] [Abstract][Full Text] [Related]
20. Role of hypoxia in skeletal muscle fibrosis: Synergism between hypoxia and TGF-β signaling upregulates CCN2/CTGF expression specifically in muscle fibers.
Valle-Tenney R; Rebolledo DL; Lipson KE; Brandan E
Matrix Biol; 2020 May; 87():48-65. PubMed ID: 31669521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
